/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Medidata Recognized as the Only Company to be Both a Leader and Star Performer in Everest Group’s 2019 Life Sciences Clinical Trials Products PEAK Matrix™
- Evaluation based upon market impact, plus vision and capability
-
Medidata positioned as top company for impact created in market,
which includes the criteria of market adoption, portfolio mix and
value delivered -
Company also designated “Star Performer,” for achieving the
greatest year-over-year improvement within the leaders segment
NEW YORK–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/clinicaltrials?src=hash” target=”_blank”gt;#clinicaltrialslt;/agt;–Medidata
(NASDAQ:MDSO) announced today that it has been named a Leader in the
Everest Group’s 2019 Life Sciences Clinical Trials Products PEAK Matrix,
based upon market impact, plus vision and capability. Medidata was also
recognized as a Star Performer, which designates the greatest positive
relative year-on-year movement on the PEAK Matrix.
“We’re thrilled to be the only company to be designated both a leader
and star performer,” said Glen de Vries, president and co-founder,
Medidata.
Everest Group noted that as a leader, Medidata has established itself as
a front runner to support life science firms looking to achieve digital
transformation within clinical trials. The report notes that leaders
have showcased:
-
An integrated end-to-end platform offering for processes across the
complete clinical trial -
A healthy mix of mid-and large-sized clientele, with accounts in many
prominent life science firms -
Technological expertise and the ability to incorporate digital
technology themes within their products - Consulting pedigree to add to strong product functionality
“The clinical trials landscape has a significant opportunity for
digitalization focused on enhancing trial efficiency, optimizing costs,
and reducing cycle time to get drugs to market faster. Currently, most
life sciences firms use disparate point solutions for different
functions across their clinical trials. Medidata is ramping up Rave and
enhancing its portfolio through Acorn AI and SHYFT. Its focus on
enabling an intelligent platform underpinned by AI positions it well to
partner with life sciences enterprises on this journey,” said Nitish
Mittal, Practice Director at Everest Group.
There are five distinguishing features which Everest Group identified
which make Medidata a Star Performer in this year’s report:
-
Introduction of Acorn AI, a platform incorporating digital technology
themes to enhance clinical trials -
Building upon its reputation for being a leading vendor in the market
for EDC solutions - High market adoption for data capture and Rave
-
Enterprise that began with only EDC solutions are expanding and
opening up to other Medidata products/solutions and expanding the
engagement -
Consulting pedigree and effort invested in understanding customers’
business
“This designation is a reflection of our strong business mission — and
the uniquely qualified expertise of our people for bringing an
innovative and game-changing solution to market. Medidata is leading the
digital transformation of clinical trials. It’s all about the patients
and getting treatments to them as fast and as safely as possible,” said
de Vries.
The
Medidata Rave Clinical Cloud is the cutting-edge platform that
transforms the clinical trial experience for patients, sponsors, CROs,
and research sites. Medidata Rave Clinical Cloud accelerates the
business of clinical research with an end-to-end suite of Rave
applications for Data Capture, Data Management, Trial Planning, Trial
Management, and Analytics powered by a rich set of Platform Tools.
About Medidata:
Medidata is leading the digital transformation of life sciences, with
the world’s most-used platform for clinical development, commercial, and
real-world data. Powered by artificial intelligence and delivered by top
ranked industry experts, Medidata helps pharmaceutical, biotech, medical
device companies, and academic researchers accelerate value, minimize
risk and optimize outcomes. Medidata and its companies, Acorn AI and
SHYFT, serve more than 1,200 customers and partners worldwide and
empower more than 150,000 certified users every day to create hope for
millions of patients. Discover the future of life sciences: www.medidata.com
Contacts
Medidata Solutions:
Investors:
Betsy
Frank, 917-522-4620
[email protected]
or
Media:
Erik
Snider, 646-362-2997
[email protected]
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Cannabis
North America Legal Cannabis Industry Report 2024: Market to Grow at a CAGR of 26.65% During 2023-2032, Bank Loans Boosting Business Growth
Cannabis
Global Legal Marijuana Strategic Business Report 2024: A $125+ Billion Market by 2030 Featuring Aphria, Aurora Cannabis, Beacon Medical, Canopy Growth, Cronos, OrganiGram, Tikun Olam, Tilray, Wayland
Cannabis
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa
-
Cannabis2 weeks ago
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
Humboldt2 weeks ago
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace
-
Cannabis2 weeks ago
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
-
Cannabis2 weeks ago
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III
-
Cannabis7 days ago
IM Cannabis Reports First Quarter Financial Results
-
Cannabis6 days ago
Mikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0
-
Innocan6 days ago
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey
-
Cannabis2 days ago
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa